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ABBREVIATIONS
IVMP Intravenous methylprednisolone
NMDAR N-methyl-D-aspartate receptor
AIM We performed the first study on the perceived benefit and adverse effects of
symptomatic management in children with anti-N-methyl-D-aspartate receptor (NMDAR)
encephalitis.
METHOD A retrospective chart review was undertaken at two tertiary paediatric hospitals in
Australia and New Zealand. We included 27 children (12 males, 15 females; mean age at
admission 7y 1mo) with anti-NMDAR antibodies in serum or cerebrospinal fluid with a typical
clinical syndrome.
RESULTS Only two out of 27 patients were white, whereas 16 out of 27 patients were from
the Pacific Islands/New Zealand Maori. The mean duration of admission was 69 days (10–
224d) and 48% of patients (13/27) needed treatment in an intensive care setting. A mean of
eight medications per patient was used for symptomatic management. Symptoms treated
were agitation (n=25), seizures (n=24), movement disorders (n=23), sleep disruption (n=17),
psychiatric symptoms (n=10), and dysautonomia (n=four). The medications used included
five different benzodiazepines (n=25), seven anticonvulsants (n=25), eight sedatives and sleep
medications (n=23), five antipsychotics (n=12), and five medications for movement disorders
(n=10). Sedative and sleep medications other than benzodiazepines were the most effective,
with a mean benefit of 67.4% per medication and a mean adverse effect-benefit ratio of 0.04
per medication. Antipsychotic drugs were used for a short duration (median 9d), and had the
poorest mean benefit per medication of 35.4% and an adverse effect-benefit ratio of 2.0 per
medication.
INTERPRETATION Long-acting benzodiazepines, anticonvulsants, and clonidine can treat
multiple symptoms. Patients with anti-NMDAR encephalitis appear vulnerable to
antipsychotic-related adverse effects. Pacific Islanders appear to have a vulnerability to anti-
NMDAR encephalitis in our region.
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis
is an antibody-mediated diffuse encephalitis that predomi-
nantly affects young adults and children. Children often
present with behavioural symptoms and then develop dis-
tinctive movement disorders combined with seizures,
encephalopathy, sleep disturbance, or dysautonomia.1,2
The use of early immune therapy has improved the recov-
ery rates in children and has been described in detail in the
literature.1 However, more than half of the patients require
second-line immune therapy, endure prolonged hospital
admissions, and require symptomatic management of
this complex disorder. There is a small body of existing
literature that discusses treatment of psychiatric symp-
toms3–5 and intensive care management6,7 in anti-NMDAR
encephalitis. We undertook a retrospective study of symp-
tomatic pharmacological management of all symptoms in
children with this condition.
METHOD
The use of medications for the symptomatic treatment of
anti-NMDAR encephalitis was reviewed at two tertiary
children’s hospitals in Australia (Children’s Hospital at
Westmead, Sydney) and New Zealand (Starship Children’s
Hospital, Auckland). These two hospitals are the largest
referral centres for children in New South Wales, Australia
and New Zealand respectively.
Twenty-seven patients diagnosed prospectively (n=13) or
retrospectively (n=14) with anti-NMDAR antibodies in
either serum or cerebrospinal fluid with typical clinical
syndromes were included in this study. All samples tested
were from the acute phase of the illness. Cerebrospinal
fluid antibodies were positive in all 21 patients tested.
Cerebrospinal fluid was not available for six retrospectively
diagnosed patients who were positive for antibodies in
serum.
© 2015 Mac Keith Press DOI: 10.1111/dmcn.12882 1
The patients had been treated by various paediatric
neurologists in each department over a 15-year period.
Ethics approval was obtained from the respective human
research ethics committees. Some patients were identified
and followed up as a part of a larger encephalitis study,8
whereas follow-up information on other patients was
obtained by correspondence, hospital records, and tele-
phonic interview.
Maori patients from New Zealand were grouped with
other patients from the Pacific Islands, including those
from New Caledonia, as Pacific Islanders. A detailed
chart review was done to identify demographic and med-
ication details during the admissions and outpatient fol-
low-up relating to the first episode of encephalitis only.
We did not include subsequent admissions in three
patients who had a relapse between 8 months to 2 years
after the first episode. Each chart was reviewed by two
reviewers at both sites, none of whom had been directly
involved in the respective patient’s clinical care. Where
required, patient records were reassessed for consensus
by two or more reviewers during final tabulation.
Medications were grouped under major categories
depending on their indication or mode of action
(Table I and Table SI, online supporting information).
We excluded medications used primarily for intensive
care-related indications such as muscle relaxants and
anaesthetizing agents such as propofol or thiopentone.
Perceived benefit from medications and adverse effects
were recorded only when there was an unambiguous
description in the medical records of benefit or adverse
effect. An adverse effect-benefit ratio was used as a descrip-
tive marker of risk versus benefit, defined as the number of
patients who had an adverse effect divided by the number
of patients who had a benefit, for each medication. Adverse
effects were graded according to the Common Terminol-
ogy Criteria for Adverse Events v4.0 (CTCAE) (available
at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-
06-14_QuickReference_5x7.pdf [accessed in May 2015]).
The doses of each medication used were compared to max-
imum doses recommended in the Australian monthly index
of medical specialties formulary (available at http://
www.mimsonline.com.au), the Children’s Hospital at
Westmead ‘in hospital’ medication guidelines, and the pae-
diatric drug formulary from the Royal Children’s Hospital,
Melbourne (available at http://www.rch.org.au/clinical-
guide/forms/drugDoses.cfm).
Modified Rankin scores9 were used to grade disease
severity at admission, during hospital stay, at discharge,
and at last available follow-up. Medical and nursing pro-
gress notes were used to ascribe modified Rankin scores at
different stages of the illness. Independent sample Stu-
dent’s t-test, v2 test, or Mann–Whitney U test were used
to compare different patient groups or other variables.
Pearson’s two-tailed correlation and Spearman’s rank cor-
relation were applied to examine correlation between num-
ber of medications used and other parameters.
RESULTS
Demographics
The demographic parameters of the cohort are described
in Table II. Sixteen patients were identified from Australia
and 11 patients from New Zealand. These included 12
male and 15 female patients. One adolescent female from
New Zealand had an ovarian teratoma. The mean age at
admission was 7 years 1 month (range 1y 1mo–14y 11mo).
The mean duration of admission was 69 days (range 10–
224d; median 62d). Forty-eight per cent of patients (13/27)
needed intensive care with a mean stay of 23 days (range
1–44d). Of the 27 patients, 16 were from the Pacific
Islands, and more patients in New Zealand (10/11) were
Pacific Islanders compared to Australia (six/16) (v2=6.9,
df=1, p<0.05). All patients were followed up for 1 year or
longer, except four patients treated in the year preceding
this study and one patient who was lost to follow-up
(Table II). The mean duration of follow-up was 3 years
6 months (range 2mo–12y 4mo, median 2y 8mo). Of the
27 patients, 15 had made a near complete recovery at the
time of the last follow-up (modified Rankin scores 0 or 1),
whereas three out of 27 patients, all Pacific Islanders, were
left with moderate to severe disability (modified Rankin
scores ≥4 at mean 3y follow-up).
Immune therapy
Twenty-three patients received first-line immune therapy
during their first admission including intravenous
immunoglobulin, intravenous methylprednisolone (IVMP),
plasma exchange, and oral prednisolone. Of the 14 patients
diagnosed retrospectively (admitted before 2007), 10 were
empirically treated with first-line immune therapy. First-
line agents were started at a median of 13 days after dis-
ease onset in prospectively diagnosed patients (mean 20d,
range 4–46d) while they were first used at a median of
21 days (mean 56d, range 8–363d) after disease onset in
patients who were not prospectively diagnosed.
Eighteen patients received intravenous immunoglobulin
at a dose of 2g/kg given over 2 to 5 days, of whom 14
were given a further two to six doses at monthly intervals.
Seventeen patients were given IVMP at a dose of 30mg/
kg/day over 3 to 6 days. Two of these seventeen were
given repeat monthly IVMP for up to 3 months. Fourteen
out of seventeen patients who received IVMP were given a
tapering dose of oral prednisolone starting at a dose of 1
to 2mg/kg/day and tapered over 2 to 10 months. Seven
patients underwent five or six cycles of double-volume
plasma exchange over 5 to 12 days.
Eight patients received a second-line agent (rituximab
n=seven; cyclophosphamide n=two; azathioprine n=one).
What this paper adds
• First descriptive study of symptomatic treatment in anti-N-methyl-D-aspartate
receptor (NMDAR) encephalitis.
• Sedating medications are helpful for management of multiple symptoms.
• Antipsychotic-related adverse effects may outweigh their benefit in anti-
NMDAR encephalitis.
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All seven patients who received rituximab were given four
weekly doses of 375mg/m2/dose. Immune therapy was gen-
erally well tolerated; however, one patient was noted to
have osteopenia leading to a femoral fracture after repeated
monthly high-dose IVMP, one patient had an intravenous
catheter site bleed, and another had an anaphylactic reac-
tion to cryoprecipitate during plasma exchange.
Symptomatic medications
A total of 33 different medications were used for symp-
tomatic treatment (Tables I and SI) with a mean of eight
medications used per patient. Even though 14 patients were
retrospectively diagnosed, they received a similar number
of symptomatic medications (mean 8) to those prospectively
diagnosed (mean 7). The number of medications used for
symptomatic treatment correlated significantly with the
duration of admission (r=0.755, p<0.001) and with the dura-
tion of intensive care unit stay (r=0.583, p<0.005). How-
ever, they did not correlate with disease severity at any
stage of the illness. There was no significant difference in
the number of medications used in those who presented
early within a week of disease onset (mean 8, median 6) and
those who presented later (mean 10, median 8).
The symptoms treated were agitation (n=25), seizures
(n=24), movement disorders (n=23; specifically, stereotypy,
n=17; chorea, n=10; dystonia, n=nine; akinesia, n=one; catato-
nia, n=three), sleep disruption (n=17), psychiatric symptoms
(n=10), and dysautonomia (n=four). Sleep disorders were
treated in more retrospectively diagnosed patients (12/14,
v2=6.5, df=1, p<0.05) compared to prospectively diagnosed
patients (five/13). Likewise, seizures were treated in 13 out of
14 retrospectively diagnosed patients compared to seven out
of 13 prospectively diagnosed patients (v2=5.3, df=1, p<0.05).
All other symptoms were treated in similar proportions of
patients in these groups. The medications used included five
different benzodiazepines (n=25), seven anticonvulsants
(n=25), eight sedatives and sleep medications (n=23), five
antipsychotics (n=12), and five medications for movement
disorders (n=10) (Tables I and SI). Themore commonly used
medications are depicted in Figure 1 with benefit and adverse
effects. Different categories of medications were used in
similar proportions of prospectively and retrospectively
diagnosed patients, except medications for movement
disorders that were used more commonly in retrospectively
diagnosed patients (eight/14) compared to prospectively
diagnosed patients (two/13, v2=5.0, df=1, p<0.05).
The benzodiazepines used included midazolam (n=23),
diazepam (n=15), lorazepam (n=10), clobazam (n=seven),
and clonazepam (n=three). These were used for indications
of agitation, seizures, movement disorders, sleep distur-
bance, and mood stabilization as listed in Table I. The
total daily doses were within recommended limits, except
for diazepam which was used in supra-maximal doses (up
to seven times the daily upper limit of normal) in 10
patients. Midazolam, used as intravenous infusion, intra-
venous bolus, or buccal dose, had the highest benefit of
91.3%. Intravenous midazolam used in the intensive careTa
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setting was often weaned slowly on the wards and switched
to buccal ‘as required’ doses. Despite the use of other con-
comitant sedative medications, benzodiazepines were gen-
erally well tolerated with adverse effects noted in only 4
out of 27 patients (see Table I for details and Common
Terminology Criteria for Adverse Events grades). These
adverse effects included excessive sedation, respiratory
depression, and sialorrhoea, and did not lead to discontinu-
ation of the medication in any patient.
Seven different anticonvulsants (in addition to benzodi-
azepines) were used for acute and ongoing management of
definite or suspected seizures. These included phenobarbi-
tal (n=17), sodium valproate (n=14), phenytoin (n=12), leve-
tiracetam (n=nine), carbamazepine (n=seven), topiramate
(n=two), and lamotrigine (n=one). Phenobarbital, sodium
valproate, and carbamazepine were also used to manage
movement disorders in some patients (Tables I and SI). In
addition, phenobarbital was used for management of agita-
tion in 10 patients and sodium valproate was used as a
mood stabilizer in one patient. The perceived benefit of
different anticonvulsants was similar, other than lamotrig-
ine and topiramate (Table I). Adverse events to anticonvul-
sants were noted in five out of 27 patients, which included
worsening agitation, thrombocytopenia, excessive sedation,
and seizure on rapid withdrawal (Table I). These events
resulted in dose adjustment of the respective medications
but did not lead to their discontinuation in any patient.
Sedative and sleep medications other than benzodi-
azepines (eight different medications) had a noted mean
benefit of 67.4% per medication. These included chloral
hydrate (n=20), clonidine (n=15), melatonin (n=13), keta-
mine (n=six), trimeprazine (n=five), dexmedetomidine
(n=two), zopiclone (n=two), and promethazine (n=one).
These medications were well tolerated with a mean adverse
effect:benefit of 0.04 per medication. Oral clonidine was
useful for managing agitation, stereotypical movements,
and sleep disturbance, and intravenous clonidine was a safe
and useful option in the intensive care unit setting.
Five different antipsychotics were used in 12 patients for
management of psychosis and/or agitation. These included
risperidone (n=eight), haloperidol (n=seven), droperidol
(n=two), thioridazine (n=two), and olanzapine (n=two).
Haloperidol was used at a high dose of 20mg/day (the
usual maximum adult dose is 15mg/day) in one adolescent.
Antipsychotics had the lowest mean benefit per medication
of 25.3% and an adverse effect-benefit ratio of 1.6 per
medication. Adverse events were noted in seven out of 12
patients treated with antipsychotics, and included dystonic
reaction (n=three with haloperidol and risperidone), neu-
roleptic malignant syndrome (n=three with risperidone and
droperidol), prolonged QT interval (n=one with haloperi-
dol), worsening agitation (n=one with olanzapine), and
dysarthria (n=one with olanzapine). The adverse effects led
to discontinuation of the respective medication and
restricted the median duration of use of antipsychotics to
only 9 days. In all cases discontinuation of the antipsy-
chotic agent led to reversal of the adverse symptoms.
In addition to the use of some benzodiazepines and anti-
convulsants for movement disorders, five medications were
used specifically for movement disorders. These included
levodopa-carbidopa (n=six), central anticholinergics (ben-
ztropine n=five; benzhexol n=one), oral baclofen (n=three),
amantadine (n=one), and bromocriptine (n=one) (Table I).
The mean benefit was only 35% per medication. Respira-
tory depression was noted with baclofen in one patient
who was also receiving benzodiazepines and other seda-
tives. This resolved on discontinuation of baclofen.
Manifestations of dysautonomia were noted in 20 out of
27 patients. Unexplained fever was treated with antipyretics
in 17 out of 27 patients, hypertension in two patients was
treated with nifedipine and clonidine, hypersalivation in two
patients was treated with glycopyrrolate and hyoscine
patches, and recurrent bradycardia and asystole in one
patient was treated with atropine and isoprenaline infusion.
Features of dysautonomia seen in six other patients (brady-
cardia, lability of blood pressure) did not require treatment.
DISCUSSION
Our cohort demonstrates the challenges faced in the man-
agement of children with anti-NMDAR encephalitis. The
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Figure 1: Medications used in five or more patients (number of patients – medication used in, benefit seen, adverse effect seen).
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patients had a mean admission of 2 months, half of the
patients required treatment in intensive care units, and the
majority of patients were given multiple medications to
manage a broad variety of symptoms. After a mean follow-
up of 3 years 7 months, 15 out of 27 (55%) patients had
made a good recovery (eight/14 patients retrospectively
diagnosed, seven/13 patients prospectively diagnosed),
whereas the remaining 12 patients were left with a range
of disability (although prolonging follow-up may have
improved reported outcomes). In a recent large case series,
approximately 75% patients were noted to make a com-
plete recovery at 2-year follow-up, and the mortality has
now fallen from 25% when this condition was initially
described to approximately 7%.1,10 Pacific Islanders made
up nearly 60% of our cohort, and the three patients with
the poorest outcome were from this group. This over-rep-
resentation of Pacific Islanders compared to other racial
groups is similar to the demographic representation among
non-whites noted in other series.11 This may suggest a vul-
nerability to disease, which could be genetically derived.
Despite improvement in long-term outcomes, symp-
tomatic management of patients during their protracted
acute illness remains a challenge for clinicians, nursing staff,
and families. In our series, we did not observe a dramatic
effect with any symptomatic medication, and the benefit
was only partial for many drugs. Medications were com-
monly used for more than one indication and sometimes
benefit was noted for one symptom and not others. How-
ever, the retrospective nature of the study and overlap
between symptoms such as stereotypical hyperkinetic move-
ments and agitation made it difficult to separate symptom-
wise benefits individually. This study was limited by the
reliance on subjective measures of benefit, but is the first
such report to describe symptomatic management in detail.
Behavioural symptoms, particularly agitation, are com-
monly seen in children with anti-NMDAR encephalitis.
Agitation was treated in 93% of patients and was often the
most distressing symptom for parents. Agitated behaviour
may be intermittent at first, becoming more frequent in
the florid stage of the illness. This agitated state has been
likened to status dissociatus12 and the dissociative state
seen with ketamine anaesthesia.13 Agitation is thought to
be caused by disruption of the frontal lobe inhibition of
thalamic–brainstem centres.14 In our cohort, sedative medi-
cations were used to treat agitation with some benefit
(Table I). Midazolam, diazepam, chloral hydrate, and
clonidine were widely used with a good adverse effect-ben-
efit ratio (0.04–0.2). Phenobarbital15 (benefit in 10/17
patients) and ketamine (benefit in six/six patients) are
antagonists of the NMDAR. Both these medications were
effective in suppressing agitation in our cohort, and no
symptomatic worsening was noted despite their effect on
the NMDAR. One previous report has described a dra-
matic sustained benefit with ketamine,16 whereas others
have not found it to be useful.6 Other candidate medica-
tions that act on the NMDAR (e.g. dextromethorphan and
memantine) have been postulated to be useful for the
symptomatic management of anti-NMDAR encephalitis,
although their clinical use is limited.17,18
Sleep disorders are common in anti-NMDAR encephali-
tis and in other autoimmune encephalopathies.19 Improved
sleep is important in the management of this and other
movement disorders, and is hypothesized to improve neu-
rological recovery.20 Clonidine was often initiated early for
sleep disturbance with an aim to eventually restrict it to a
night-time dose, along with early use of melatonin. We
did not have any concerns with rebound hypertension with
the use of clonidine in this cohort of patients, although
blood pressure monitoring is recommended especially
when clonidine is stopped after short use (Table III).
For sleep induction, we also used sedative medications
including benzodiazepines starting with an intermediate–
long-acting benzodiazepine such as clobazam or loraze-
pam, supplemented by buccal midazolam or chloral
hydrate when needed. Similar to clonidine, the dosing of
sedative medications was shifted towards evening/night-
time doses as patients tolerated weaning to smaller doses,
to try and maintain a sleep–wake diurnal cycle. We are also
mindful of the use of environmental measures such as
ambient lighting and timing of physical interventions like
physiotherapy and play therapy during daylight hours to
assist in correction of the sleep–wake cycle.
Movement disorders are noted in the majority of chil-
dren with anti-NMDAR encephalitis and were treated in
85% of our series. The movements are often hyperkinetic
and stereotyped with perseverative components, as recently
described.21 Symptomatic treatment is often initiated to
facilitate patient care, and to avoid the risks of injury and
rhabdomyolysis, in addition to reducing patient and paren-
tal distress. Sedative medications such as benzodiazepines
and some anticonvulsants appeared to be beneficial in
managing movement disorders in our cohort, and were
similar to the drugs used to treat agitation. ‘Conventional’
movement disorder medications such as levodopa and cen-
tral anticholinergics had a more modest benefit. This is
possibly because the origin of abnormal movements in
anti-NMDAR encephalitis is not purely caused by a basal-
ganglia dysfunction involving dopaminergic pathways. We
tend to use these medications infrequently now as reflected
by the decreasing use in prospectively diagnosed patients
in this cohort. Our current approach is to choose medica-
tions that have a broad effect on multiple symptoms if
possible. Hence, we increasingly rely on long-acting ben-
zodiazepines, sedatives such as clonidine, and anticonvul-
sants such as phenobarbital or sodium valproate to try to
improve abnormal movements or stabilize mood. Loraze-
pam is helpful in the treatment of catatonia, and electro-
convulsive therapy has been successfully used to treat
catatonia in anti-NMDAR encephalitis, although we did
not use electroconvulsive therapy in our cohort.22,23
The management of psychiatric symptoms was more chal-
lenging. While sedative medications again helped manage
aggression and mood lability, the use of antipsychotic medi-
cations was less efficacious and was associated with adverse
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Table III: Suggested practice points for selected medications used in anti-N-methyl-D-aspartate receptor encephalitis (doses used as per local
guidelines)
Medication group Indications Monitoring Comment
IVMP First-line immune
suppression
Blood pressure, blood glucose AE due to IVMP such as agitation, psychosis,
and hypertension may be difficult to separate
from disease manifestations
IVIG First-line immune
suppression
Monitor for dysautonomia,
allergic reactions, and signs of
aseptic meningitis
If AE occur, a slower rate or infusion can be
used. Premedication with antihistaminic
agents can minimize allergic reactions
Plasmapheresis First-line immune
suppression
Therapeutic drug levels of
anticonvulsants
AE related to medication withdrawal may
occur
Benzodiazepines
Midazolam Agitation
Stereotypies
Sleep disorders
Monitor for respiratory
depression with concomitant
sedative use
Buccal or intranasal doses are good rescue
options for periods of agitation or intractable
stereotypies and seizures but intravenous
infusion may be needed
Other benzodiazepines Agitation
Seizures
Stereotypies
Catatonia
Sleep disorders
Monitor for respiratory
depression with concomitant
sedative use
Consider use of lorazepam for perseverative
symptoms and other features of catatonia
Substitute infusions for oral doses and taper
to avoid withdrawal symptoms
Anticonvulsants
Phenobarbital Agitation
Seizures
Movement disorders
Supra-therapeutic drug levels
may sometimes be tolerated if
benefit seen and respiratory
status is not compromised
Taper doses when stopping
Sodium valproate Agitation
Seizures
Chorea
Psychiatric symptoms
Monitor blood counts and liver
function
Useful for multiple symptoms, particularly for
mood stabilization
Levetiracetam Seizures
Movement disorders
Behavioural worsening and agitation may
occur and may be difficult to separate from
disease symptoms
Topiramate Seizures Speech regression, mood disturbance, and
mutism are known AE and may be difficult to
separate from disease symptoms
Sedative and sleep medications
Chloral hydrate Agitations
Stereotypies
Sleep disorder
Monitor for cumulative sedation
with other agents
Safe with multiple doses in our experience.
Useful for PRN use. Paradoxical agitation
may occur in some cases
Clonidine Agitation
Sleep disorder
Stereotypies
Blood pressure for hypotension
at low doses and rebound
hypertension when stopping
Monitor for excessive sedation
Hypotension is a concern at low doses
Can be used 2–3 hourly as oral doses,
infusion can be used
Ketamine Agitation, stereotypies Monitor for cumulative sedation
and respiratory depression
Insufficient data for use outside ICU setting
No AE noted with infusions
Melatonin Sleep disorder Sleep induction is supported by timing doses
of sedative medications with melatonin
Dexmedetomidine Agitation
Movement disorder
Sleep disorder
Monitor for cumulative sedation
with other agents
Mechanism of action is similar to clonidine
and is more expensive
Antipsychotics
Risperidone
Haloperidol
Thioridazine
Olanzapine
Droperidol
Psychiatric symptoms
Agitation
Monitor for extrapyramidal AE,
QT prolongation
Cardiovascular AE with long-
term use
High rate of AE
Consider use of anticonvulsants or more
selective antipsychotics at low starting doses
Atypical antipsychotics –
Quetiapine, Aripiprazole
Psychiatric symptoms
Agitation
Monitor for extrapyramidal AE,
QT prolongation
Cardiovascular AE with long-
term use
Risk of NMS and Tardive dyskinesia
Long-term safety/outcome data is not
available
Medications for movement disorders
Levodopa Dystonia Dopamine responsiveness of dystonia is
unclear in this setting
Anticholinergics Dystonia (disease or
drug-related)
Agitation, gut hypomotility as AE may be
difficult to separate from disease symptoms
Baclofen Dystonia
Movement disorders
Respiratory depression Hypotonia and respiratory depression. Limited
benefit – preferably avoid
AE, adverse effect; IVMP, intravenous methylprednisolone; IVIG, intravenous immunoglobulin; PRN, pro re nata (as required); ICU, inten-
sive care unit; NMS, neuroleptic malignant syndrome.
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events. In this series antipsychotic use was associated with
dystonic reaction or neuroleptic malignant syndrome in
58% patients treated, and these side effects improved on dis-
continuation of the medication. Previous reports24–26 have
also noted this predisposition to antipsychotic-related
adverse events in anti-NMDAR encephalitis. These observa-
tions suggest a higher vulnerability to antipsychotic-related
adverse effects in children with anti-NMDAR than the pre-
viously reported 14% to 18% incidence in children treated
for delirium or other indications.27 Patients with Sydenham
chorea also appear to have a vulnerability to antipsychotic-
induced adverse events with drug-related parkinsonism seen
in 5.5% of patients in one series.28 We hypothesize that
agents such as quetiapine with less dopamine-2 receptor
blockade may be better tolerated. In our practice we initiated
antipsychotics cautiously, and have tried to use very low
starting doses with gradual titration (Table III).
Seizures are seen in the acute stage of anti-NMDAR
encephalitis and remit in most cases within a few months.1,29
In our series, rescue medications for seizures were not
required after the first month of illness. Some patients (n=7)
were empirically given anticonvulsants without proven sei-
zures. While maintenance anticonvulsants were sometimes
continued for 2 years or longer, it is possible that these med-
ications could be weaned earlier to reduce potential side
effects. No anticonvulsant had a clear advantage, and we
have chosen agents that may help other symptoms such as
agitation, stereotypies, or mood disturbance (phenobarbital,
sodium valproate, and longer-acting benzodiazepines).
It is important to recognize and treat dysautonomia
when present. Cardiac rhythm disturbances, asystole (as
seen in one patient), and lability of blood pressure can all
be life-threatening. Sometimes these symptoms, particu-
larly changes in heart rate and blood pressure, can be exac-
erbated with the use of high-dose steroids and intravenous
immunoglobulin.30
The physiological explanation for many symptoms seen
in anti-NMDAR encephalitis and consequently the mecha-
nism by which certain medications help, remains unre-
solved. There is clear evidence of NMDAR hypofunction
resulting from the antibodies in in vitro studies; however,
the effect on other neurotransmitters and receptors is not
clear. Immune therapy is the mainstay of treatment and
early escalation to second-line agents is key to early and
complete recovery when symptoms do not improve in the
first few weeks of illness. Although this study focused on
pharmacological measures, the role of parental involvement
and support, nursing care, and rehabilitative and allied
health input cannot be overstated.
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